POTOMAC, MARYLAND – August 05, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments for Alzheimer’s and
– Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings –
POTOMAC, MARYLAND – July 21, 2025 – IGC Pharma, Inc. (NYSE American: IGC) a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that its Principal Scientist, Jagadeesh Rao, Ph.D.,
Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer’s diagnostics
POTOMAC, MARYLAND – June 30, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and
POTOMAC, MARYLAND – June 27, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced that the Company will host a conference call and webcast on
We are presenting a poster named “Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay” at The Genetic Toxicology Association (GTA) Meeting 2025 held at the Clayton Hall
Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.
By: Faith Ashmore Benzinga Staff Writer As of 2023,, the estimated number of Americans living with Alzheimer’s disease was 6.7 million. However, a lesser-known subsection of Alzheimer’s is Agitation in
By: Faith Ashmore Benzinga Staff Writer Alzheimer’s disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact